Effect of Landiolol as an adjunct to Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction

UMIN ID: UMIN000001872

Registered date:11/04/2009

Basic Information

• Recruitment status: Complete: follow-up continuing
• Health condition(s) or Problem(s) studied: Acute myocardial infarction
• Date of first enrollment: 2009/04/01
• Target sample size: 88
• Countries of recruitment: Japan
• Study type: Interventional

Intervention(s)

Intraveous landiolol administation
Placebo

Outcome(s)

• Primary Outcome: Estimated infarct size (AUC of creatine kinase)
• Secondary Outcome: 1) Estimated infarct size (AUC of CK-MB) 2) Infarct size on 99mTc-MIBI SPECT

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: 80years-old
• Gender: Male and Female
• Exclude criteria: 1) history of OMI or CABG 2) LMT 3) suspected aortic dissection 4) systolic blood pressure of less than 90 mmHg or bradycardia of less than 60 beats/min 5) more than II-AV block or 2 bundle block 6) severe liver and/or kidney dysfunction 7) bronchial athma 8) history of beta-blocker or amiodarone 9) history of side effects or contraindication of beta-blocker

Related Information

• Primary Sponsor: Cardiovascular Division, University of Tsukuba, Graduate School of Comprehensive Human Sciences
• Source(s) of Monetary Support: None